“Two doses of the four approved vaccines protect against the Delta variant.” The confirmation comes from the EMA, in the person of the head of the vaccine strategy of the Marco Cavaleri agency. The effectiveness of completing the vaccination cycle was highlighted by the ‘reassuring’ data available from the European Pharmacovigilance Body. Which underlines how “important it is to continue vaccination with particular attention to the most vulnerable people and the elderly”. The evidence gathered by the experts, however, does not carry “any definitive recommendations”, as noted by Cavaleri himself. “At the moment, the EMA is unable to provide a definitive recommendation on the use of different Covid vaccines for the two doses,” he explains, “but preliminary data from studies in Spain and Germany show a good immune response and no problems safety”. On the strategies to be followed, however, for vaccination with different drugs between first and second inoculation, Cavaleri reiterates that “heterologous vaccination has historically proved to be successful, has been used for other vaccines and has a solid scientific logic”. At the moment, the Ema will have to express itself by the summer on 5 therapeutic treatments chosen by the European Commission. “All five treatments selected by the European Commission as part of its therapeutic strategy are under review”, concludes Cavaleri, “The first opinions are expected by the end of the year”.